Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
Alkermes plc.
SIC 2834 · Pharmaceutical Preparations
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Alkermes plc.
SIC 2834 · Pharmaceutical Preparations
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Alkermes plc.
SIC 2834 · Pharmaceutical Preparations
Notes
Support
about
terms
$
ALKS
Alkermes plc.
CIK:
0001520262
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
REVENUES:
Total revenues
$ 496,009
$ 390,657
$ 888,920
$ 697,167
EXPENSES:
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)
98,112
49,460
159,690
98,657
Research and development
112,920
77,370
216,265
149,187
Selling, general and administrative
217,625
170,849
482,218
342,553
Change in fair value of contingent consideration
26,414
0
26,414
0
Amortization of acquired intangible assets
22,585
0
34,260
0
Total expenses
477,656
297,679
918,847
590,397
OPERATING (LOSS) INCOME
18,353
92,978
(29,927)
106,770
OTHER (EXPENSE) INCOME, NET:
Interest income
5,344
11,090
13,883
21,231
Interest expense
(25,925)
0
(46,817)
0
Other (expense) income, net
352
771
(941)
2,327
Total other (expense) income, net
(20,229)
11,861
(33,875)
23,558
(LOSS) INCOME BEFORE INCOME TAXES
(1,876)
104,839
(63,802)
130,328
INCOME TAX PROVISION (BENEFIT)
(2,377)
17,741
2,177
20,766
Net (loss) income
$ 501
$ 87,098
$ (65,979)
$ 109,562
(LOSS) EARNINGS PER ORDINARY SHARE:
(Loss) earnings per ordinary share- basic
$ 0
$ 0.53
$ (0.4)
$ 0.67
(Loss) earnings per ordinary share - diluted
$ 0
$ 0.52
$ (0.4)
$ 0.65
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:
Basic
167,026
164,959
166,613
164,188
Diluted
173,478
168,357
166,613
168,470
COMPREHENSIVE (LOSS) INCOME:
Net Income (Loss)
$ 501
$ 87,098
$ (65,979)
$ 109,562
Holding (loss) gain, net of a tax (benefit) provision of $78, $16, $249 and $184, respectively
(255)
55
(823)
567
Foreign currency translation gain
240
0
0
0
COMPREHENSIVE (LOSS) INCOME
486
87,153
(66,802)
110,129
Product sales, net
REVENUES:
Total revenues
411,724
307,235
749,838
551,728
Manufacturing and royalty revenues
REVENUES:
Total revenues
$ 84,285
$ 83,422
$ 139,082
$ 145,439
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income
$ (65,979)
$ 109,562
Adjustments to reconcile net income to cash flows from operating activities:
Depreciation and amortization
49,705
15,239
Amortization of inventory step-up
43,728
0
Share-based compensation expense
67,469
47,776
Change in fair value of contingent consideration
26,414
0
Deferred income taxes
317
(900)
Other non-cash charges
5,577
3,245
Changes in assets and liabilities:
Receivables
(72,062)
29,622
Contract assets
(6,751)
3,566
Inventory
1,014
(10,043)
Prepaid expenses and other assets
(20,960)
16,163
Right-of-use assets
4,355
3,713
Accounts payable and accrued expenses
(78,286)
56,109
Accrued sales discounts, allowances and reserves
23,550
(19,279)
Contract liabilities
0
(671)
Operating lease liabilities
(5,661)
(5,137)
Other long-term liabilities
7,010
48
Cash flows (used in) provided by operating activities
(20,560)
249,013
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions of property, plant and equipment
(12,236)
(23,126)
Proceeds from the sale of property, plant and equipment
9
34
Proceeds from the sale of the Athlone facility
0
1,708
Business combination, net of cash acquired
(2,085,073)
0
Purchases of investments
(44,804)
(193,806)
Sales and maturities of investments
62,693
195,078
Cash flows used in investing activities
(2,079,411)
(20,112)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of ordinary shares under share-based compensation arrangements
42,006
31,611
Proceeds from the issuance of debt, net
1,511,557
0
Deferred financing costs paid to third-parties
(2,980)
0
Employee taxes paid related to net share settlement of equity awards
(24,538)
(30,459)
Payment for the repurchase of ordinary shares
(27,696)
0
Principal payments of long-term debt
(6,625)
0
Cash flows provided by financing activities
1,491,724
1,152
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS
(608,247)
230,053
CASH, CASH EQUIVALENTS AND RESTRICTED CASH-Beginning of period
1,119,776
291,146
CASH, CASH EQUIVALENTS AND RESTRICTED CASH-End of period
511,529
521,199
SUPPLEMENTAL CASH FLOW DISCLOSURE:
Cash paid for taxes
13,926
1,591
Non-cash investing and financing activities:
Purchased capital expenditures included in accounts payable and accrued expenses
4,260
7,562
Unpaid contingent consideration
$ 107,713
$ 0
v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
CURRENT ASSETS:
Cash and cash equivalents
$ 511,529
$ 388,570
Restricted cash
0
731,206
Investments—short-term
145,048
199,645
Receivables, net
456,477
334,025
Inventory
298,957
196,625
Prepaid expenses and other current assets
110,895
79,090
Total current assets
1,522,906
1,929,161
PROPERTY, PLANT AND EQUIPMENT, NET
218,284
221,722
INVESTMENTS—LONG-TERM
35,054
145
RIGHT-OF-USE ASSETS
76,111
77,209
INTANGIBLE ASSETS, NET
1,761,456
815
GOODWILL
594,273
83,027
DEFERRED TAX ASSETS
123,041
125,815
OTHER ASSETS
62,000
49,099
TOTAL ASSETS
4,393,125
2,486,993
CURRENT LIABILITIES:
Accounts payable and accrued expenses
332,469
289,565
Accrued sales discounts, allowances and reserves
295,645
247,126
Operating lease liabilities—short-term
7,477
6,746
Current portion of long-term debt
26,500
0
Total current liabilities
662,091
543,437
OPERATING LEASE LIABILITIES—LONG-TERM
61,976
63,253
CONTINGENT CONSIDERATION
136,304
0
LONG-TERM DEBT
1,476,611
0
DEFERRED TAX LIABILITIES
179,575
0
OTHER LONG-TERM LIABILITIES
68,018
61,008
Total liabilities
2,584,575
667,698
COMMITMENTS AND CONTINGENT LIABILITIES (Note 18)
SHAREHOLDERS’ EQUITY:
Preferred shares, par value, $0.01 per share: 50,000,000 shares authorized; and zero issued and outstanding at June 30, 2026 and December 31, 2025, respectively.
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 184,700,718 and 181,011,166 shares issued; and 167,541,198 and 165,607,028 shares outstanding at June 30, 2026 and December 31, 2025, respectively
1,847
1,810
Treasury shares, at cost (17,159,520 and 15,404,138 shares at June 30, 2026 and December 31, 2025, respectively)
(502,521)
(450,287)
Additional paid-in capital
3,112,920
3,004,666
Accumulated other comprehensive loss
(2,923)
(2,100)
Accumulated deficit
(800,773)
(734,794)
Total shareholders’ equity
1,808,550
1,819,295
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
$ 4,393,125
$ 2,486,993